Hemispherx Biopharma, Inc. announced earnings results for the first quarter ended March 31, 2013. For the quarter, the company's net loss (including non-cash effects) was approximately $3,611,000 or $0.02 per share as compared to a net loss of $2,308,000 or $0.02 per share for the same three month period in 2012. This first quarter-to-quarter increase in net loss of approximately $1,303,000 was predominantly caused by: an increase of approximately $671,000 related to continued efforts to seek FDA approval of the Ampligen(R) NDA for Chronic Fatigue Syndrome and preparations for commercial manufacturing at its New Brunswick, NJ facility; approximately $95,000 in higher non-cash stock compensation to strategic consultants supporting the overall Ampligen(R) commercialization effort; and a decrease of approximately $642,000 from sales of New Jersey State net operating loss carry forwards.

Hemispherx Biopharma, Inc. announced financial results for the year ended December 31, 2012. The net loss for 2012's twelve month period (including non-cash effects) was approximately $17,354,000 or $0.12 per share as compared to a net loss of $9,015,000 or $0.07 per share for the same period in 2011. This year-to-year increase in net loss of approximately $8,339,000 (93%) was predominantly caused by: the cost of its continued efforts to seek FDA approval of the Ampligen(R) NDA for Chronic Fatigue Syndrome and preparations for FDA inspections of its New Brunswick, NJ manufacturing facility; the cost of fill, finish and packaging of Alferon N Injection(R) Work-In-Process inventory along with a related valuation write-down of existing inventory to the lower of cost or market; and the fair value revaluation of the estimated liability related to certain redeemable warrants resulting in a non-cash gain of $85,000 in 2012 as compared to a gain of $2,425,000 for the same period in 2011 for an increased loss of $2,340,000 comparing the two years. The net cash used in operating activities for the twelve month period of 2012 would be approximately $13,136,000 as compared to $10,096,000 for 2011, resulting in an increase in cash used for operations of approximately $3,040,000 or 30%.

Hemispherx Biopharma, Inc. announced that ANMAT (Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica), the agency responsible for the national regulation of drugs, foods and medical technology in Argentina, has approved the use of Alferon N Injection(R) (under the brand name "Naturaferon") in Argentina for any patient that fails or becomes intolerant to treatment with recombinant interferon. Alferon N Injection(R) is an FDA-approved natural interferon and, as Naturaferon, is already approved in Argentina for the treatment of refractory or recurring external condylomata acuminata (genital warts). Patients on recombinant interferon can become intolerant to treatment with the side effects outweighing the benefits of the therapy. In addition, patients can become refractory to such treatment because they develop antibodies to recombinant interferon which can dramatically reduce its effectiveness. The fraction of relapsed and refractory patients was reported as statistically greater in NAB positive patients compared to NAB negative patients (p < 0.0001), whereas the percentage of responding patients was reported as higher in NAB negative patients (p < 0.001). Another analysis looked at relapsed and refractory NAB positive patients who were then switched to natural interferon. Across all the different diseases the authors reviewed, 33 out of 40 or 82% of these patients had their clinical response restored after switching to natural interferon.